Article
Homozygosity for killer immunoglobin-like receptor haplotype A predicts complete molecular response to treatment with tyrosine kinase inhibitors in chronic myeloid leukemia patients.
Experimental hematology - 1 May 2013
La Nasa Giorgio, Caocci Giovanni, Littera Roberto, Atzeni Sandra, Vacca Adriana, Mulas Olga, Langiu Marzia, Greco Marianna, Orrù Sandro, Orrù Nicola, Floris Andrea, Carcassi Carlo
Abstract excerpt
Several recent reports suggest a possible role for killer immunoglobulin-like receptors (KIR) in the onset of chronic myeloid leukemia (CML) and response to therapy with tyrosine kinase inhibitors (TKIs). To explore this hypothesis, we studied KIRs and their human leukocyte antigen class I ligands in 59 consecutive patients with chronic-phase CML (mean age, 53 years; range, 23-81 years) and a group of 121 healthy...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.